The studies below are .. flawed .. since a 'new hypothesis has been
advanced' .. meaning .. the ACTUAL .. iron 'load' was never ..
addressed.
The study was halted .. too .. soon ..
Cell Mol Biol (Noisy-le-grand). 2000 Jun;46(4):865-9. Related Articles,
Links
A multiple course trial of desferrioxamine in chronic progressive
multiple sclerosis.
Lynch SG, Fonseca T, Levine SM.
Department of Neurology, University of Kansas Medical Center, Kansas
City 66160, USA. [email hidden]
Chronic progressive multiple sclerosis (MS) is a debilitating disease
that is often refractory to treatment. We have previously published a
pilot study using a single 2-week course of the iron chelating drug,
desferrioxamine (DFO), as a candidate drug for treatment of this form
of MS. In this study, we gave 9 patients up to 8 courses of this
regimen over 2 years. The patients tolerated the medication well.
During the study, 1 patient improved, 3 remained stable, and 5 worsened
by 0.5 on the Kurtzke expanded disability status scale (EDSS). These
results suggest that, while the drug is well tolerated, no effect on
disease progression can be identified at this dosage level. A more
continuous dosage schedule could be studied as a candidate for
treatment in this disease process.
Publication Types:
Clinical Trial
PMID: 10875447 [PubMed - indexed for MEDLINE
--------------------------------------------------------------------------------
Brain Res. 1999 Mar 13;821(2):511-5. Related Articles, Links
Ferritin, transferrin and iron concentrations in the cerebrospinal
fluid of multiple sclerosis patients.
LeVine SM, Lynch SG, Ou CN, Wulser MJ, Tam E, Boo N.
Department of Molecular and Integrative Physiology and the Mental
Retardation and Human Development Center, University of Kansas Medical
Center, Kansas City, KS 66160, USA. [email hidden]
The concentrations of ferritin, transferrin and iron were measured in
the cerebrospinal fluid (CSF) of multiple sclerosis (MS) and control
patients. Ferritin levels were significantly elevated in the CSF of
chronic progressive active MS patients (4.71+/-0.54 ng/ml) compared to
levels in normal individuals (3.07+/-0.17 ng/ml). MS patients with
active or stable relapsing-remitting disease had ferritin levels that
were comparable to those found in normal individuals. There were no
significant differences in transferrin or iron levels in the CSF
between MS and normal individuals. Both ferritin and transferrin levels
were elevated in patients that had high CSF IgG values but not in
patients with a high IgG index. Since ferritin binds iron, the increase
of CSF ferritin levels in chronic progressive MS patients could be a
defense mechanism to protect against iron induced oxidative injury.
Ferritin levels could be a laboratory measure that helps to distinguish
between chronic progressive and relapsing-remitting MS. Copyright 1999
Elsevier Science B.V.
PMID: 10064838 [PubMed - indexed for MEDLINE]
--------------------------------------------------------------------------------
Who loves ya.
Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore
DEAD PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking